Respiratory function of patients with parkinson disease and its correlation with motor symptoms and quality of life: long term investigation

Aim of the study was to investigate respiratory function of patients with Parkinson’s disease and its correlation with clinical symptoms and their quality of life. Especially we compare the three main motor symptoms of the disease (tremor, dyskinesia, bradykinesia) with respiratory function parameters and we correlate them with the stage of the disease. In three years we follow up these patients so we were able to compare disease aggregation with respiratory function. Special questionnaires were used in order to evaluate quality of life of these patients during the first examination. The severity of illness affected the respiratory function in small and large airways. The correlation of sf 36 dimensions between patients suffering from Parkinson and healthy individuals, demonstrated influence of the disease in general health, role functional and functional capability.Σκοπός της μελέτης είναι η διερεύνηση της αναπνευστικής λειτουργίας σε ασθενείς με νόσο Parkinson και συσχέτιση αυτής με την κλινική συμπτωματολογία και την ποιότητα ζωής των ασθενών αυτών. Μελετήθηκαν 56 ασθενείς. Έγινε έλεγχος της αναπνευστικής λειτουργίας (αέρια αίματος, στοματικές πιέσεις) και συσχετισμός αυτής με το στάδιο της νόσου και τη βαρύτητα της βάσης της κλίμακας UPDRS. Ελέγχθηκε κατά πόσο τα τρία κύρια χαρακτηριστικά της νόσου(τρόμος, βραδυκινησία, δυσκαμψία) επηρεάζουν την αναπνευστική λειτουργία των ασθενών. Ο ίδιος έλεγχος έγινε και τρία χρόνια μετά την πρώτη εξέταση. Τέλος καταγράφηκε και αξιολογήθηκε η ποιότητα ζωής των ασθενών κατά την πρώτη εξέταση. Βρέθηκε ότι το στάδιο της νόσου επηρεάζει στις μικρές αεροφόρους οδούς. Επίσης η επιδείνωση του σταδίου και της βαρύτητας της νόσου επηρεάζει τις μικρές και μεγάλες αεροφόρους οδούς. Η επιδείνωση της δυσκαμψίας και της βραδυκινησίας επηρεάζει τις μικρές και μεγάλες αεροφόρους. Τέλος, η ποιότητα ζωής των ασθενών με νόσο Parkinson είναι σαφώς επιδεινωμένη σε σχέση με υγιείς μάρτυρες σε σχέση με υγιείς μάρτυρες

Immunotherapy and Chemotherapy Versus Sleep Disturbances for NSCLC Patients

Introduction: Cancer patients are known to experience sleep disturbances that differ between disease stages and treatments. Regarding lung cancer patients and immunotherapy, information on their sleep disturbances has been recently acquired, but no comparison has been made between different treatment modalities. Patients and Methods: We recruited 98 non-small cell lung cancer patients; 49 had programmed death-ligand 1 expression of ≥50% and received immunotherapy as first-line treatment and 49 had programmed death-ligand 1 expression in the range from 0–49 and received chemotherapy as first-line treatment. All patients were stage IV, but with no bone metastasis. Sleep disturbances were recorded through polysomnography and sleep questionnaires. Results: For immunotherapy patients with PD-L1 expression ≥ 50%, the disease response was rapid and the sleep disturbances decreased rapidly. On the other hand, for chemotherapy patients, the sleep disturbances remained for all those patients that had partial response and stable disease. It was noticed that chemotherapy drugs induce severe adverse effects. Discussion: In our study, it was observed that patients with complete response had reduced sleep disturbances in the case of immunotherapy patients. However, sleep disturbances continued for several patients in the chemotherapy group due to the adverse effects of chemotherapy drugs. In conclusion: Immunotherapy drugs on their own do not induce sleep disturbances and, through treatment response, alleviate sleep disturbances in lung cancer patients